Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its stock offering and the subsequent acquisition by AbbVie Inc. [1][2] Group 1: Allegations and Impact - The lawsuit claims that Cerevel's October 16, 2023 secondary stock offering omitted crucial information about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which led to an artificially deflated stock price until the merger announcement [2] - Bain Capital, Cerevel's controlling shareholder, allegedly purchased shares during the October Offering while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding$120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - Cerevel's January 18, 2024 Proxy statement is accused of misleading investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or held shares from October 11, 2023, to August 1, 2024, and those who sold shares contemporaneously with Bain Capital's purchase on October 16, 2023 [1][2] - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost or obligation to participate [3] - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3] Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors from deceit and illegal business practices [4] - The firm emphasizes the importance of responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to stock price inflation [4]